Jun 12, 2020
EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
Mar 17, 2020
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Jan 13, 2020
John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma
Jan 06, 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 10, 2019
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Dec 09, 2019
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
Dec 04, 2019
First Industry Datasets Submitted to ASH Research Collaborative Data Hub
Dec 04, 2019
International Myeloma Foundation Presents Research, Video Reports, Social Media Coverage at 2019 American Society of Hematology Meeting (ASH)
Nov 21, 2019
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSA(TM) (zanubrutinib)